IP Library Granted Patent US 11,426,393
Granted Patent B2
US 11,426,393 · App. 16/908,092 · Granted Aug 30, 2022

Prolyl hydroxylase inhibitors and methods of use

Inventors: Richard Masaru Kawamoto (Divide, CO); Shengde Wu (West Chester, OH); Artem G. Evdokimov (Foristell, MO); Kenneth D. Greis (Fort Thomas, KY); Angelique Sun Boyer (West Chester, OH); Namal C. Warshakoon (Cary, NC)
Assignee: Akebia Therapeutics, Inc.
A61K31/4418A61K31/4433C07C235/60C07C237/42C07C255/57C07D213/65C07D213/81C07D295/192C07D401/04C07D401/10C07D405/04C07D405/10C07D417/04Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,393
App. No.
16/908,092
Granted
Aug 30, 2022
Kind
B2
Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Claims (22)

1. A process for preparing a compound having the formula:

or a pharmaceutically acceptable salt thereof,

comprising:

reacting 3-chlorophenyl boronic acid:

with [(3-hydroxy-5-trifluoromethanesulfonyloxy-pyridine-2-carbonyl)-amino]acetic acid methyl ester:

in the presence of a catalyst to form the following compound:

2. The process of claim 1 , wherein the [(3-hydroxy-5-trifluoromethanesulfonyloxy-pyridine-2-carbonyl)-amino]acetic acid methyl ester:

is prepared by a process comprising:

(a) reacting 3,5-dichloro-2-cyanopyridine:

with benzyl alcohol to form 3,5-bis-benzyloxy-pyridine-2-carbonitrile:

(b) reacting 3,5-bis-benzyloxy-pyridine-2-carbonitrile obtained from step (a) with sodium hydroxide to form 3,5-bis-benzyloxy-pyridine-2-carboxylic acid:

(c) reacting 3,5-bis-benzyloxy-pyridine-2-carboxylic acid obtained from step (b) with glycine methyl ester:

in the presence of coupling reagents to form [(3,5-bis-benzyloxy-pyridine-2-carbonyl)-amino]-acetic acid methyl ester:

(d) reacting [(3,5-bis-benzyloxy-pyridine-2-carbonyl)-amino]-acetic acid methyl ester obtained from step (c) under an atmosphere of H 2 in the presence of a catalyst to form [(3,5-dihydroxy-pyridine-2-carbonyl)-amino]-acetic acid methyl ester:

and

(e) reacting [(3,5-dihydroxy-pyridine-2-carbonyl)-amino]-acetic acid methyl ester obtained from step (d) with N-phenyl trifluoromethansulfonimide ((CF 3 SO2) 2 NC 6 H 5 ) to form [(3-hydroxy-5-trifluoromethanesulfonyloxy-pyridine-2-carbonyl)-amino]acetic acid methyl ester:

3. The process of claim 1 , further comprising reacting {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester:

with sodium hydroxide to form {(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid:

4. The process of claim 1 , wherein the catalyst is [1,1′-bis (diphenylphosphino)ferrocine]dichloro palladium(II).

5. The process of claim 1 , wherein the reaction is conducted in the presence of a base that is K 3 PO 4 .

6. The process of claim 2 , wherein the coupling reagents in step (c) are 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (MCI) and 1-hydroxybenzotriazole (HOBt).

7. The process of claim 2 , wherein the catalyst in step (d) is Pd/C.

Assignments (5)
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: KAWAMOTO, RICHARD MASARU
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 055786/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: WU, SHENGDE; WARSHAKOON, NAMAL C.; EVDOKIMOV, ARTEM G.; GREIS, KENNETH D.; BOYER, ANGELIQUE SUN
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 055786/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 055787/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: THE PROCTER & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 055791/0337 →
Continuity (10)
Continuation 16119146 · Aug 31, 2018
Continuation 15420617 · Jan 31, 2017
Continuation 14854080 · Sep 15, 2015
Continuation 14568200 · Dec 12, 2014
Continuation 14062011 · Oct 24, 2013
Division 13681876 · Nov 20, 2012
Continuation 12860073 · Aug 20, 2010
Continuation 11821936 · Jun 26, 2007
Provisional Application 60816522 · Jun 26, 2006
Related Publication 20210137901A1 · May 13, 2021
Cited By (5)
US 12,478,615 US 12,569,474 US 12,612,367 US 12,629,357 US 12,703,691